Taxanes in combination with biologic agents for ovarian and breast cancers.

Roshan Karki, Brandon Luke L Seagle, Wilberto Nieves-Neira, Shohreh Shahabi

Research output: Contribution to journalArticle

Abstract

Taxane-based cytotoxic therapy is commonly prescribed for breast and ovarian cancers. Although these cancers are often sensitive to such therapy, clinical benefit and overall survival are limited owing to the development of chemoresistance and recurrence. Biologic agents that specifically target proteins of growth factor signaling pathways, which are hyperactivated in cancers, offer attractive targets for cancer therapeutics and may work synergistically with standard taxane-based chemotherapy to improve patient outcomes. We review clinical trials of biologic agents--angiogenic, tyrosine kinase, and antibody inhibitors--in combination with taxane-based therapy for ovarian and breast cancers. Many clinical trials have shown promising results. However, some biologic agents still need larger trials to assess safety and efficacy. As research into the heterogeneity and complexity of ovarian and breast cancers improves our understanding of the molecular pathways involved, there is no question that targeted therapies with biologic agents will expand the future array of available cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)536-554
Number of pages19
JournalAnti-Cancer Drugs
Volume25
Issue number5
StatePublished - 2014
Externally publishedYes

Fingerprint

Taxoids
Biological Factors
Ovarian Neoplasms
Breast Neoplasms
Neoplasms
Therapeutics
Clinical Trials
Protein-Tyrosine Kinases
Intercellular Signaling Peptides and Proteins
Safety
Recurrence
Drug Therapy
Survival
Antibodies
Research
taxane
Proteins

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research
  • Oncology

Cite this

Karki, R., Seagle, B. L. L., Nieves-Neira, W., & Shahabi, S. (2014). Taxanes in combination with biologic agents for ovarian and breast cancers. Anti-Cancer Drugs, 25(5), 536-554.

Taxanes in combination with biologic agents for ovarian and breast cancers. / Karki, Roshan; Seagle, Brandon Luke L; Nieves-Neira, Wilberto; Shahabi, Shohreh.

In: Anti-Cancer Drugs, Vol. 25, No. 5, 2014, p. 536-554.

Research output: Contribution to journalArticle

Karki, R, Seagle, BLL, Nieves-Neira, W & Shahabi, S 2014, 'Taxanes in combination with biologic agents for ovarian and breast cancers.', Anti-Cancer Drugs, vol. 25, no. 5, pp. 536-554.
Karki R, Seagle BLL, Nieves-Neira W, Shahabi S. Taxanes in combination with biologic agents for ovarian and breast cancers. Anti-Cancer Drugs. 2014;25(5):536-554.
Karki, Roshan ; Seagle, Brandon Luke L ; Nieves-Neira, Wilberto ; Shahabi, Shohreh. / Taxanes in combination with biologic agents for ovarian and breast cancers. In: Anti-Cancer Drugs. 2014 ; Vol. 25, No. 5. pp. 536-554.
@article{ec5cee224b634ab38d893c605ab7d7b1,
title = "Taxanes in combination with biologic agents for ovarian and breast cancers.",
abstract = "Taxane-based cytotoxic therapy is commonly prescribed for breast and ovarian cancers. Although these cancers are often sensitive to such therapy, clinical benefit and overall survival are limited owing to the development of chemoresistance and recurrence. Biologic agents that specifically target proteins of growth factor signaling pathways, which are hyperactivated in cancers, offer attractive targets for cancer therapeutics and may work synergistically with standard taxane-based chemotherapy to improve patient outcomes. We review clinical trials of biologic agents--angiogenic, tyrosine kinase, and antibody inhibitors--in combination with taxane-based therapy for ovarian and breast cancers. Many clinical trials have shown promising results. However, some biologic agents still need larger trials to assess safety and efficacy. As research into the heterogeneity and complexity of ovarian and breast cancers improves our understanding of the molecular pathways involved, there is no question that targeted therapies with biologic agents will expand the future array of available cancer therapeutics.",
author = "Roshan Karki and Seagle, {Brandon Luke L} and Wilberto Nieves-Neira and Shohreh Shahabi",
year = "2014",
language = "English (US)",
volume = "25",
pages = "536--554",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Taxanes in combination with biologic agents for ovarian and breast cancers.

AU - Karki, Roshan

AU - Seagle, Brandon Luke L

AU - Nieves-Neira, Wilberto

AU - Shahabi, Shohreh

PY - 2014

Y1 - 2014

N2 - Taxane-based cytotoxic therapy is commonly prescribed for breast and ovarian cancers. Although these cancers are often sensitive to such therapy, clinical benefit and overall survival are limited owing to the development of chemoresistance and recurrence. Biologic agents that specifically target proteins of growth factor signaling pathways, which are hyperactivated in cancers, offer attractive targets for cancer therapeutics and may work synergistically with standard taxane-based chemotherapy to improve patient outcomes. We review clinical trials of biologic agents--angiogenic, tyrosine kinase, and antibody inhibitors--in combination with taxane-based therapy for ovarian and breast cancers. Many clinical trials have shown promising results. However, some biologic agents still need larger trials to assess safety and efficacy. As research into the heterogeneity and complexity of ovarian and breast cancers improves our understanding of the molecular pathways involved, there is no question that targeted therapies with biologic agents will expand the future array of available cancer therapeutics.

AB - Taxane-based cytotoxic therapy is commonly prescribed for breast and ovarian cancers. Although these cancers are often sensitive to such therapy, clinical benefit and overall survival are limited owing to the development of chemoresistance and recurrence. Biologic agents that specifically target proteins of growth factor signaling pathways, which are hyperactivated in cancers, offer attractive targets for cancer therapeutics and may work synergistically with standard taxane-based chemotherapy to improve patient outcomes. We review clinical trials of biologic agents--angiogenic, tyrosine kinase, and antibody inhibitors--in combination with taxane-based therapy for ovarian and breast cancers. Many clinical trials have shown promising results. However, some biologic agents still need larger trials to assess safety and efficacy. As research into the heterogeneity and complexity of ovarian and breast cancers improves our understanding of the molecular pathways involved, there is no question that targeted therapies with biologic agents will expand the future array of available cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=84908387799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908387799&partnerID=8YFLogxK

M3 - Article

VL - 25

SP - 536

EP - 554

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 5

ER -